Dr. Beverly Moy
LightNews LightNews
beverlymoy.bsky.social
Dr. Beverly Moy
@beverlymoy.bsky.social
130 followers 76 following 2 posts
Medical Oncologist, Clinical Director of Breast Oncology, Vice Chief of Quality, Safety, and DEI at Mass General Cancer Center. Professor at Harvard Medical School. Views my own.
Posts Replies Media Videos
beverlymoy.bsky.social
@ascocancer.bsky.social #ASCOGuidelines out today "Systemic Therapy for Stage I-III Anal Carcinoma" with guidance about radiosensitization, dose/scheduling options, and much more. @vanmorrismd.bsky.social @cathyengmd.bsky.social Read at society.asco.org/practice-pat...
Gastrointestinal Cancer
Gastrointestinal Cancer
society.asco.org
December 16, 2024 at 11:48 PM
beverlymoy.bsky.social
No matter what's happening in the world, it's so great to know that you have the very best colleagues in the world at Mass General Brigham Breast Center. @ethicsdoctorp.bsky.social and many others. So thankful for them this Thanksgiving.
November 26, 2024 at 2:46 AM
Reposted by Dr. Beverly Moy
brittanyeharvey.bsky.social
New rapid recommendation update on systemic therapy for small-cell lung cancer from ASCO just published: ascopubs.org/doi/full/10.... #ASCOguidelines #MedSky #OncSky #LCSM
Visual abstract for Systemic Therapy for SCLC Rapid Guideline Update: 2.4. Patients with LS-SCLC who have completed concurrent chemoradiotherapy and do not have disease progression should be offered consolidation immunotherapy (durvalumab) for up to 2 years if there are no contraindications to immunotherapy. (Evidence quality: Moderate; Strength of recommendation: Strong) 5.3.1. Patients with LS-SCLC and ECOG PS 3-4 due to SCLC who have been treated with concurrent or sequential chemotherapy and radiotherapy may be offered consolidation immunotherapy (durvalumab) for up to 2 years if there are no contraindications to immunotherapy and there is improvement in PS. (Evidence quality: Low; Strength of recommendation: Conditional) 4.1. In patients with relapsed SCLC with a chemotherapy-free interval of less than 90 days, single-agent systemic therapy may be offered. Preferred agents are topotecan, lurbinectedin or tarlatamab. (Evidence quality: Moderate; Strength of recommendation: Strong) 4.2. In patients with relapsed SCLC with a chemotherapy-free interval of at least 90 days, re-challenge with a platinum-based regimen or single-agent chemotherapy (preferred agents are topotecan, lurbinectedin or tarlatamab) may be offered. (Evidence quality: Moderate; Strength of recommendation: Strong) Kalemkerian et al J Clin Oncol 2024 asco.org/thoracic-cancer-guidelines
November 20, 2024 at 9:39 PM